Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Daily Healthcare St. Lucia.
Press releases published on August 19, 2025
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
August 19, 2025
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, …
Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC
GlobeNewswire
·
August 19, 2025
NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with myeloproliferative neoplasms, today announced the appointment …
COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
GlobeNewswire
·
August 19, 2025
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient has been dosed in the Phase 1b/2a …
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
GlobeNewswire
·
August 19, 2025
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging …
Milestone® Pharmaceuticals to Present at Upcoming Conferences
GlobeNewswire
·
August 19, 2025
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place …
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
GlobeNewswire
·
August 19, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds …
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
GlobeNewswire
·
August 19, 2025
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) …
Global Central Lab Services Market to Reach USD 8.18 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 19, 2025
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global Central Lab Services Market, valued at US$5.64 billion in 2024, stood at US$5.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a …
Aveanna to Participate at the Deutsche Bank Healthcare Summit
GlobeNewswire
·
August 19, 2025
ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Healthcare Summit in New York on September 10, 2025. Management will host 1x1 …
Global Negative Pressure Wound Therapy Market to Surpass USD 3.84 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 19, 2025
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global negative pressure wound therapy market, valued at US$2.59 billion in 2024, stood at US$2.76 billion in 2025 and is projected to advance at a resilient CAGR of 6.9% from 2025 to 2030, …
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewswire
·
August 19, 2025
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage …
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
GlobeNewswire
·
August 19, 2025
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today …
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
GlobeNewswire
·
August 19, 2025
- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology …
Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science
GlobeNewswire
·
August 19, 2025
First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers The Company recently announced the results from its Phase II placebo-controlled clinical trial of …
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
August 19, 2025
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …
Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
GlobeNewswire
·
August 19, 2025
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4 Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE …
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
GlobeNewswire
·
August 19, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent No. US-2022/0133806 A1, covering the company's …
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
August 19, 2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
GlobeNewswire
·
August 19, 2025
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
GlobeNewswire
·
August 19, 2025
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE trial will be …